Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
24 août 2021 09h20 HE
|
Adhera Therapeutics, Inc.
Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.)Laboratory and clinical research support MLR-1023 as the...